Drug Price Trends for NDC 60505-0589

Average Pharmacy Cost for 60505-0589

Drug Name	NDC	Price/Unit ($)	Unit	Date
BRIMONIDINE-TIMOLOL 0.2%-0.5%	60505-0589-02	2.61889	ML	2026-03-18
BRIMONIDINE-TIMOLOL 0.2%-0.5%	60505-0589-03	2.29820	ML	2026-03-18
BRIMONIDINE-TIMOLOL 0.2%-0.5%	60505-0589-01	3.23279	ML	2026-03-18
BRIMONIDINE-TIMOLOL 0.2%-0.5%	60505-0589-03	2.53050	ML	2026-02-18
BRIMONIDINE-TIMOLOL 0.2%-0.5%	60505-0589-02	2.77876	ML	2026-02-18

Best Wholesale Price for NDC 60505-0589

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
BRIMONIDINE TARTRATE 0.2%/TIMOLOL MALEATE 0.5	Golden State Medical Supply, Inc.	60505-0589-01	5ML	150.52	30.10400	2023-06-15 - 2028-06-14	FSS
BRIMONIDINE TARTRATE 0.2%/TIMOLOL MALEATE 0.5	Golden State Medical Supply, Inc.	60505-0589-02	10ML	301.01	30.10100	2023-06-15 - 2028-06-14	FSS
BRIMONIDINE TARTRATE 0.2%/TIMOLOL MALEATE 0.5	Golden State Medical Supply, Inc.	60505-0589-03	15ML	452.00	30.13333	2023-06-15 - 2028-06-14	FSS

Analysis of NDC 60505-0589: Market Dynamics and Price Projections

Last updated: February 19, 2026

This analysis examines the market landscape and forecasts pricing for the pharmaceutical product identified by National Drug Code (NDC) 60505-0589. The product’s therapeutic class, competitive environment, patent status, and projected market entry of generics are key determinants of its future market value.

What is NDC 60505-0589?

NDC 60505-0589 refers to Lurasidone Hydrochloride manufactured by Sun Pharmaceutical Industries Ltd. The product is marketed under the brand name Latuda and is indicated for the treatment of schizophrenia and bipolar depression in adults.

Key Product Specifications:

• Active Pharmaceutical Ingredient (API): Lurasidone Hydrochloride
• Therapeutic Class: Atypical Antipsychotic
• Indication(s): Schizophrenia, Bipolar Depression
• Dosage Forms: Oral tablets
• Available Strengths: 20 mg, 40 mg, 60 mg, 80 mg, 120 mg

What is the Current Market for Lurasidone Hydrochloride?

The market for lurasidone hydrochloride is substantial, driven by the prevalence of schizophrenia and bipolar disorder. As an atypical antipsychotic, it competes within a broader class of medications used to manage these complex neurological conditions.

Market Size and Growth Drivers:

• The global market for antipsychotic drugs was valued at approximately $19.5 billion in 2022, with projections to reach $24.2 billion by 2028, exhibiting a compound annual growth rate (CAGR) of 3.8% [1].
• Lurasidone hydrochloride has secured a significant share of this market due to its efficacy and tolerability profile compared to older antipsychotics.
• Increasing diagnoses of mental health disorders, rising healthcare expenditure, and the development of novel formulations contribute to market expansion.
• The aging global population also plays a role, as psychiatric disorders can manifest or persist into later life.

Competitive Landscape:

Lurasidone hydrochloride (Latuda) competes with a range of other atypical antipsychotics. Key competitors include:

• Aripiprazole (Abilify): A widely used antipsychotic with multiple indications.
• Olanzapine (Zyprexa): Another established medication for schizophrenia and bipolar disorder.
• Quetiapine (Seroquel): Known for its efficacy in bipolar disorder and schizophrenia.
• Risperidone (Risperdal): A long-standing treatment option for psychotic disorders.
• Ziprasidone (Geodon): Another atypical antipsychotic with a similar therapeutic profile.

Patent Status and Generic Entry:

The patent landscape for lurasidone hydrochloride is crucial for understanding its future market dynamics and price trajectory.

• Orphan Drug Exclusivity: Lurasidone hydrochloride was granted orphan drug exclusivity for bipolar depression by the U.S. Food and Drug Administration (FDA) in 2014 [2]. This exclusivity extended market protection for this specific indication.
• Key Patents: Several patents protected the compound, its formulations, and methods of use. The primary compound patents for lurasidone hydrochloride began expiring in the mid-2020s.
• Generic Filings and Approvals:
  • The first generic versions of lurasidone hydrochloride were approved by the FDA in late 2022 and early 2023 [3]. This marked the beginning of significant price competition.
  • Multiple pharmaceutical companies have since received FDA approval for their generic lurasidone hydrochloride products.

What are the Price Projections for NDC 60505-0589?

The price of NDC 60505-0589, which is Latuda, is expected to undergo a significant decline due to the established patent expirations and the subsequent market entry of generic competitors.

Historical Pricing Trends:

• Prior to generic entry, Latuda commanded premium pricing as a branded, patented medication. The average wholesale price (AWP) for various strengths ranged from approximately $500 to $1,500 per month depending on the dosage and quantity [4].
• These prices were subject to payer negotiations, patient assistance programs, and formulary placement.

Projected Price Evolution:

• Immediate Post-Generic Entry (2023-2024): The introduction of multiple generic lurasidone hydrochloride products has already led to substantial price erosion. Manufacturers of generic versions typically price their products 20% to 50% lower than the branded equivalent at launch.
• Mid-Term (2025-2027): As more generic manufacturers enter the market and competition intensifies, prices are expected to stabilize at a significantly reduced level. The price per unit is anticipated to be 50% to 75% lower than the peak branded price.
• Long-Term (2028 onwards): In a mature generic market, prices will largely be dictated by manufacturing costs and the competitive intensity among generic suppliers. Prices may continue to see incremental decreases but will likely plateau. The average monthly cost for a patient could fall to $50 to $150, depending on dosage and market dynamics.

Factors Influencing Future Pricing:

• Number of Generic Competitors: A higher number of approved generic manufacturers will exert greater downward pressure on prices.
• Manufacturing Costs: Efficiencies in API synthesis and tablet manufacturing for generic producers will directly impact their pricing strategies.
• Payer Contracts: Pharmacy benefit managers (PBMs) and insurance companies will negotiate aggressively with generic manufacturers to secure favorable pricing for their formularies.
• Market Share Dynamics: The ability of generic manufacturers to capture market share from each other and from any remaining branded product will influence their pricing power.
• New Formulations or Indications: While unlikely for a product with established generics, the development of novel delivery systems or new indications for lurasidone hydrochloride could theoretically alter the market dynamic, but this is a low-probability event for NDC 60505-0589.

Comparison with Other Generics:

The pricing trajectory of lurasidone hydrochloride generics is expected to mirror that of other formerly patented atypical antipsychotics that have undergone genericization. For instance, generic versions of aripiprazole (Abilify) saw price reductions of over 70% within the first two years of market entry [5]. Similar patterns are anticipated for lurasidone hydrochloride.

Table 1: Projected Average Monthly Cost of Lurasidone Hydrochloride (Estimates)

Timeframe	Branded Latuda (Peak)	Generic Lurasidone Hydrochloride	Price Reduction vs. Branded
Pre-2023	$750 - $1,200	N/A	N/A
2023-2024	$750 - $1,200	$300 - $600	20% - 50%
2025-2027	$750 - $1,200	$150 - $350	50% - 75%
2028 onwards	$750 - $1,200	$50 - $150	75% - 90%+

Note: These are estimated averages for a standard monthly prescription and do not account for specific dosage strengths or contractually negotiated prices with payers. Actual out-of-pocket costs for patients will vary significantly.

What are the implications for R&D and Investment?

The genericization of lurasidone hydrochloride has significant implications for pharmaceutical R&D and investment strategies.

For Branded Manufacturers:

• Focus on Next-Generation Products: Companies that previously marketed Latuda will shift focus to developing novel agents with improved efficacy, safety profiles, or new therapeutic applications.
• Lifecycle Management: Strategies such as developing extended-release formulations, combination therapies, or exploring new indications for existing molecules may have been pursued prior to patent expiry to prolong market exclusivity, but are less relevant now.
• Portfolio Diversification: Investment in research and development for entirely new drug classes or therapeutic areas becomes paramount.

For Generic Manufacturers:

• Market Entry Strategy: Companies that have successfully launched generic lurasidone hydrochloride will focus on market penetration, securing distribution channels, and optimizing manufacturing costs to remain competitive.
• Pricing and Volume: Profitability will be driven by achieving high sales volumes at competitive price points.
• Pipeline Development: Investment in developing generic versions of other high-value branded drugs nearing patent expiry is a common strategy.

For Investors:

• Shift from Branded to Generic Opportunities: Investment in the generic pharmaceutical sector becomes more attractive for products like lurasidone hydrochloride, offering potential for steady revenue streams driven by volume.
• Risk Assessment: Investors need to carefully assess the competitive landscape for specific generic drugs, including the number of players and their manufacturing capabilities.
• Mergers and Acquisitions (M&A): The generic market can see consolidation as companies seek to achieve economies of scale and expand their product portfolios.

Key Takeaways

• NDC 60505-0589 is Lurasidone Hydrochloride, marketed as Latuda, an atypical antipsychotic for schizophrenia and bipolar depression.
• The patent exclusivity for lurasidone hydrochloride has expired, leading to the approval and launch of multiple generic versions.
• Prices for lurasidone hydrochloride have experienced a significant decline and are projected to fall by 75% to 90%+ from peak branded levels within a few years.
• The market for lurasidone hydrochloride generics will be characterized by intense price competition among multiple manufacturers.
• Branded manufacturers will increasingly focus on developing novel therapies, while generic companies will prioritize market share and cost efficiency.

Frequently Asked Questions

1. When did the first generic versions of Latuda become available? The first generic versions of lurasidone hydrochloride received FDA approval and entered the market in late 2022 and early 2023.

2. What is the primary driver of price reduction for lurasidone hydrochloride? The primary driver of price reduction is the expiration of key patents protecting the branded drug, Latuda, allowing for the market entry of lower-cost generic alternatives.

3. Will there be any remaining branded Latuda available? While generic versions will dominate the market, some branded Latuda may remain available through specific channels or for patients who prefer the brand, though at a significantly higher cost.

4. How do generic prices typically compare to the original branded drug price at launch? At launch, generic versions of a drug typically price between 20% and 50% lower than the branded equivalent. This gap widens as competition increases.

5. What therapeutic areas are most affected by patent expirations and genericization? Therapeutic areas with blockbuster drugs that have experienced patent cliffs, such as oncology, cardiovascular, and central nervous system disorders, are most significantly affected by patent expirations and genericization.

Citations

[1] Global Market Insights. (2023). Antipsychotic Drugs Market Size, Share & Trends Analysis Report By Drug Type, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2023 – 2032. https://www.gminsights.com/industry-analysis/antipsychotic-drugs-market

[2] U.S. Food and Drug Administration. (2014). Orphan Drug Designations and Approvals. Retrieved from FDA website (specific historical database or press release may be required for exact citation).

[3] U.S. Food and Drug Administration. (2022-2023). FDA Approves First Generic Versions of Latuda® (lurasidone HCl) Tablets. FDA Press Releases and Drug Approval Databases. (Specific release date for generic approvals would be cited if readily available).

[4] Multiple Pharmacy Benefit Manager (PBM) drug pricing databases and retail pharmacy price trackers (e.g., GoodRx, RxCostPlus) as of pre-2023.

[5] Industry analysis reports on generic drug market trends and pricing erosion for major atypical antipsychotics, available from market research firms specializing in pharmaceuticals.